Tysabri testing underway
Biogen Idec aims to use drug for cancer
Biogen Idec Inc. still hopes to find new uses for its multiple sclerosis drug Tysabri, even though some patients have contracted a potentially fatal brain disease. (Full article: 601 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
